ECEESPE2025 ePoster Presentations Endocrine Related Cancer (100 abstracts)
The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study
Aspasia Manta 1 , Afroditi Roumpou 1 , Maria Gerogianni 1 , Roubini Zakopoulou 2 , Kimon Tzannis 2 , Areti Mamali 2 , Vasiliki Malamatini 2 , Konstantina Kakogianni 2 , Aristotelis Bamias 2 & Melpomeni Peppa 1,3
1Attikon University Hospital, Endocrine Unit, Second Propaedeutic Department of Internal Medicine, Research Institute and Diabetes Center, Athens, Greece; 2Attikon University Hospital, Second Propaedeutic Department of Internal Medicine, Research Institute and Diabetes Center, Athens, Greece; 3Sotiria General Hospital for Chest Diseases, Third Department of Internal Medicine, Athens, Greece
JOINT3327
Urothelial carcinoma (UC) is a prevalent malignancy of the urinary system. Muscle-invasive UC is associated with significant morbidity and mortality. Metabolic syndrome (MetS), characterized by a combination of obesity, hypertension, dyslipidemia, and insulin resistance, has been implicated in various cancers, including UC. However, its impact on UC prognosis remains underexplored. This study aims to assess the association between MetS and survival outcomes in UC patients. A single-center retrospective study was conducted, analyzing 112 patients with histologically confirmed UC, diagnosed between January 2018 and February 2024. Patients were categorized based on the presence of MetS (≥ 3 criteria) or its individual components. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were evaluated using Kaplan–Meier estimates and Cox proportional hazard regression models, adjusting for disease stage and other covariates. Of the 112 patients (82.1% males, with a median age at diagnosis of 71.9 years [IQR 65.8-79]), 49 (43.8%) met the criteria for MetS. In a multivariable analysis, patients with MetS exhibited significantly worse OS and PFS compared to those without MetS (HR: 2.04, 95% CI 1.13-3.68, P = .018; HR: 2.13, 95% CI 1.11-4.1, P = .024, respectively), after adjusting for disease stage and other covariates. Among individual MetS components, diabetes had the strongest association with reduced survival (HR: 3.33, 95% CI 1.59-6.98, P = .001 for OS). Hypertension also emerged as an independent predictor of poor OS (HR: 1.96, 95% CI 1.04-3.73, P= .039). MetS and its components, particularly diabetes and hypertension, are associated with poorer survival outcomes in UC patients. These findings highlight the need for integrating metabolic health management into UC treatment strategies to improve patient outcomes.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more